Ractigen Therapeutics Kicks Off Multi-Center Phase II Clinical Trial of First-in-Class saRNA Therapeutic RAG-01 for Non-Muscle Invasive Bladder Cancer
- Written by PR Newswire
- Trial initiated at Fudan University Shanghai Cancer Center (FUSCC) under the leadership of Leading Principal Investigator Professor Ding-Wei Ye, uniting 11 premier urologic oncology centers across China
- Phase II study incorporates a safety run-in phase with a subsequent multi-cohort design to evaluate intravesical RAG-01 both as a monotherapy and...














